Celgene Corporation (CELG) recently presented data from various studies on its oncology drugs at the annual meeting of the American Society of Clinical Oncology (TATD) held in the US.
Celgene presented detailed data from the MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study (n=861), which evaluated its oncology drug Abraxane in combination with Eli Lilly and Company’s (LLY) Gemcitabine as a first-line therapy in patients suffering from advanced pancreatic cancer.
Data from the study revealed that there was significant improvement in overall survival in patients treated with Abraxane and Gemzar compared to those treated with Gemzar alone. The median progression-free survival of 8.5 months was observed in the Abraxane plus Gemzar arm compared to 6.7 months for patients in the Gemzar arm.
We note that Abraxane is under priority review in the US for the advanced pancreatic cancer indication. Abraxane in combination with Gemzar is also under review in the EU for the same indication.
Celgene also presented data from a study, which evaluated its key oncology drug Revlimid as a combination therapy versus autologous stem cell transplant with or without Revlimid maintenance in newly-diagnosed multiple myeloma (MM) patients.
Data revealed a longer median progression-free survival and overall survival rate for patients in the stem cell transplant arm compared to those treated with the Revlimid combination. Moreover, maintenance therapy with Revlimid resulted in a statistically significant reduction in the risk of disease progression while causing improvement in overall survival irrespective of prior therapy.
Celgene also presented encouraging updated data from an international late-stage study (MM-003) which evaluated Pomalyst combined with low-dose dexamethasone versus high-dose dexamethasone in previously treated MM patients. Data from a study (MM-008) evaluating Pomalyst in patients suffering from renal impairment was also presented by Celgene at the ASCO.
Celgene, a biopharmaceutical company, currently carries a Zacks Rank #2 (Buy). Alexion Pharmaceuticals, Inc. (ALXN) and Cubist Pharmaceuticals, Inc. (CBST) look equally attractive in the biopharma space with a Zacks Rank #2 each.
More From Zacks.com